Alkermes Controlled Therapeutics, Inc. Ii

Janssen Pharmaceutica

Other

Janssen Pharmaceutica Nv

Alkermes, Inc.

Hercon Laboratories Corporation

Thomas J Atkins

Michael E Rickey

Jean Louis Mesens

J Michael Ramstack

Paul F Herbert

Jan Strobel

Douglas E Buerger

Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.

Method of treating warm blooded animals suffering from psychotic disorders. The method includes administering a pharmaceutically effective amount of sustained-release microparticles that include risperidone, or a pharmaceutically acceptable acid addition salt thereof, and a biodegradable and biocompatible polymeric matrix.

The invention relates to a method of treating psychotic disorders comprising a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof.

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and

Cosmetic products and methods of performing skin treatments are disclosed. The products and methods are especially suitable for removing keratotic plugs from the pores of skin. The cosmetic products are based on formulations including non-ionic, film-forming, solvent-activatable polymers as major active ingredients. Especially preferred formulations include N-vinyl formamide as in poly(N-vinyl formamide) as a major active ingredient. In some cases, the formulations are coated onto a backing material to form a patch in order to increase the utility and ease of use of the products. The products are used to remove keratotic plugs by applying the product to the skin, allowing the product to dry, and peeling the product from the skin. Also disclosed is a method for producing the preferred articles provided by the invention.

Pore cleaning product

The invention relates to a pharmaceutical composition comprising a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof, within a polymeric matrix.

The instant invention is related to a sustained-release microparticle produced by dissolving in a solvent an active agent and a biodegradable and biocompatible polymer to form an organic phase.

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles

A pharmaceutical composition comprising a biodegradable and biocompatible composition comprising a 1,2 benzazole within a polymeric matrix. The 1,2 benzazole composition, pharmaceutically acceptable acid addition salts thereof, are potent antagonists of a series of neurotransmitters, particularly serotonin and dopamine. A method of inhibiting both serotonergic overactivity and dopaminergic overstimulation in animals is provided by administration of a biodegradable and biocompatible microparticle composition comprising a 1,2 benzazole or a pharmaceutically acceptable acid addition salt thereof. A method of treating warm blooded animals suffering from psychotic disorders, and a method of preparing the biodegradable and biocompatible composition are also described.

Method of inhibiting neurotransmitter activity using microencapsulated

Disclosed herein is a process for preparing biodegradable microparticles comprising a biodegradable polymeric binder and a biologically active agent, wherein a blend of at least two substantially non-toxic solvents, free of halogenated hydrocarbons, is used to dissolve or disperse the agent and dissolve the polymer. The solvent blend containing the agent and polymer is dispersed in an aqueous solution to form microdroplets. The resulting emulsion is then added to an extraction medium preferably containing at least one of the solvents of the blend, whereby the rate of extraction of each solvent is controlled, whereupon the biodegradable microparticles containing the biologically active agent are formed.

Growing community of inventors

York, PA, United States of America

Thomas J Atkins